Helsinn appoints Dr Melanie Rolli as Group Chief Operating Officer

20 May 2022

Helsinn to present data at upcoming AMMF’s 2022 European Cholangiocarcinoma Conference

17 May 2022

Knight Therapeutics and Helsinn Healthcare SA Enter into Exclusive License, Distribution, and Supply Agreement for Akynzeo® and Aloxi®

17 May 2022

United States Ambassador Scott Miller meets the Chairman of Farma Industria Ticino Association

12 May 2022

Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets*

6 May 2022

Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFB)

27 April 2022

FIT premia il miglior lavoro di diploma nella Tecnica dei sistemi chimico-farmaceutica della SSST

29 March 2022

Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris® I.V. Infusion 235mg in Japan

28 March 2022

Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.

4 March 2022

Verity PharmaceuticalsTM and Helsinn Therapeutics sign exclusive agreement for the promotion of Akynzeo® and Valchlor® in Puerto Rico

18 February 2022